Minaris Advanced Therapies
Eytan Abraham currently serves as the Chief Commercial and Technology Officer at Minaris Advanced Therapies since January 2025 and holds a Board Member position at Noga Therapeutics from January 2021. Previously, Eytan Abraham was a Board Observer at CTMC, a joint venture between Resilience and MD Anderson Cancer Center, from January 2024 to January 2025, and served as VP and Business Head of Cell, Gene and Nucleic Acids Franchises at Resilience from September 2021 to January 2025. Eytan Abraham also held a Board Member role at Cellevolve from December 2021 to August 2023. Eytan Abraham completed a post doctorate in Tissue Engineering and Cell Therapy at Harvard Medical School from January 2008 to December 2010 and earned a degree in Finance for Executives from INSEAD in 2017.
This person is not in any teams
This person is not in any offices
Minaris Advanced Therapies
1 followers
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 730,000 square feet of infrastructure across the United States, Europe and Asia. We have manufactured and released over 7,500 GMP batches and our global network supports therapy developers through early-stage development, clinical trials and commercial manufacturing. By combining scientific expertise with best-in-class manufacturing and testing services, we help bring safe, effective therapies to patients faster and more efficiently. With more than 20 years’ experience in the field of regenerative medicine, we are trusted partner ensuring scalability, delivering high quality results, and achieving cost effective manufacturing. Our state-of-the-art facilities in the United States, Europe, and Asia, as well as our committed employees, enable us to supply patients worldwide with lifechanging therapies. Minaris Advanced Therapies is wholly owned by Altaris, LLC.